Recent Updates
Recently added Catalysts

rAAV2/5-PBGD

Phase 1

Acute Intermittent Porphyria | Gene Therapies | Rare Disease |uniQure N.V.|Trials Updated: Dec 18, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

rAAV2/5-PBGD clinical trials

rAAV2/5-PBGD · 1 trial · 1 indication

Phase 1 1
NCT02082860Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaAcute Intermittent Porphyria
COMPLETED8 Analytics
PHASE1COMPLETED
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Acute Intermittent PorphyriaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of patients with Adverse Events and Serious Adverse Events
Up to 48 weeks

To assess the safety and determine the maximum therapeutic safe dose of the investigational gene therapy (GT) product rAAV2/5-PBGD for the treatment of AIP, registering and evaluating the occurrence of Adverse Events and/or Serious Adverse Events at the dose identified will be performed

Secondary Endpoints

Effect of the treatment on porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) urinary level.
Up to 48 weeks
Clinical evolution of acute intermittent porphyria. Frequency of hospitalizations
Up to 48 weeks
Frequency of treatments for AIP symptoms
Up to 48 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort AEXPERIMENTALrAAV2/5-PBGD vector dosage 1
Cohort BEXPERIMENTALrAAV2/5-PBGD vector dosage 2
Cohort CEXPERIMENTALrAAV2/5-PBGD vector dosage 3
Cohort DEXPERIMENTALrAAV2/5-PBGD vector dosage 4

Interventions

NameTypeDescription
rAAV2/5-PBGD vector dosage 1GENETICIntravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
rAAV2/5-PBGD vector dosage 2GENETICIntravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
rAAV2/5-PBGD vector dosage 3GENETICIntravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
rAAV2/5-PBGD vector dosage 4GENETICIntravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 64 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Patient's written Informed Consent * Age between 18 and 64 years, inclusively. * Patients with confirmed diagnosis of Acute Intermittent Porphyria(AIP), as confirmed by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation. The p...

Countries:Spain
Unlock Eligibility Criteria

Frequently asked questions about rAAV2/5-PBGD

What is rAAV2/5-PBGD?

rAAV2/5-PBGD is an investigational gene therapy developed by uniQure N.V. for acute intermittent porphyria. It is a recombinant adeno-associated viral vector designed to deliver a gene to patients with this rare inherited metabolic disorder. It has been studied in a single Phase 1 clinical trial conducted in Spain.

What is rAAV2/5-PBGD used for in acute intermittent porphyria?

rAAV2/5-PBGD is being studied as a gene therapy treatment for acute intermittent porphyria, a rare inherited disorder of heme metabolism. The approach aims to address the underlying genetic defect rather than manage symptoms alone. The only clinical trial of rAAV2/5-PBGD enrolled adults 18 years and older with the condition.

Who makes rAAV2/5-PBGD?

rAAV2/5-PBGD is developed by uniQure N.V., a gene therapy company whose shares trade under the ticker QURE. uniQure sponsored the Phase 1 clinical trial of the vector for acute intermittent porphyria. The program is part of the company's gene therapy portfolio in rare disease.

What phase is rAAV2/5-PBGD in?

rAAV2/5-PBGD is in Phase 1 development. Its single clinical trial, NCT02082860, has been completed. The study was a controlled Phase 1 gene therapy trial with 8 enrolled participants, conducted in Spain in adults aged 18 years and older. rAAV2/5-PBGD is investigational and has not been approved by the FDA.

What clinical trials is rAAV2/5-PBGD in?

rAAV2/5-PBGD has been evaluated in one clinical trial, NCT02082860, titled a Phase I gene therapy clinical trial using the vector rAAV2/5-PBGD for the treatment of acute intermittent porphyria. The trial is completed, enrolled 8 participants, was controlled but not randomized or double blind, and took place in Spain.